A Study of RO5036505 in Patients With Moderate to Severe Asthma

Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma. Patients will be randomized to receive either RO5036505 (380mg iv infusion once weekly) or placebo for 8 weeks. Patients will be on a standardized inhaled corticosteroid/long-acting beta-agonist regimen during study treatment. Target sample size is 50-100 individuals.

Timeline

Start

2009-09

Primary completion

—

Completion

2010-08

Outcome

Outcome not reported

Stopped: “No patients dosed”

Drugs

Indications